drugset / Trial / NCT04170543
A Phase 2b Diabetic Kidney Disease Study
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease
Timeline
- Start
- 2019-11-18
- Primary completion
- 2023-05-16
- Completion
- 2023-05-16
Publications
- Hofherr A, Maki-Petaja K, Selvarajah V, Grice D, Bartesaghi S, Jimenez E, Pecoits-Filho R, Heerspink HJL. Inhibition of IL-33 in Diabetic Kidney Disease: A Randomized, Placebo-Controlled Phase 2b Trial. J Am Soc Nephrol. 2026 May 1;37(5):1022-1033. doi: 10.1681/ASN.0000000966. Epub 2025 Dec 5.
- Hofherr A, Liarte Marin E, Musial B, Seth A, Slidel T, Conway J, Baker D, Hansen PBL, Challis B, Bartesaghi S, Bhat M, Pecoits-Filho R, Tu X, Selvarajah V, Woollard K, Heerspink HJL. Inhibition of Interleukin-33 to Reduce Glomerular Endothelial Inflammation in Diabetic Kidney Disease. Kidney Int Rep. 2024 Mar 18;9(6):1876-1891. doi: 10.1016/j.ekir.2024.03.009. eCollection 2024 Jun.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tozorakimab | Monoclonal antibody | 30 mg | — |
| Subject | Tozorakimab | Monoclonal antibody | 60 mg | — |
| Subject | Tozorakimab | Monoclonal antibody | 120 mg | — |
| Subject | Tozorakimab | Monoclonal antibody | 300 mg | — |
| Background | Dapagliflozin | Small molecule | 10 mg | Oral |